09:47 AM EDT, 05/06/2025 (MT Newswires) -- Viridian Therapeutics ( VRDN ) shares were down 1.7% in recent Tuesday trading after the company reported a Q1 net loss earlier Tuesday of $0.87 per diluted share, wider than a loss of $0.59 a year earlier.

Four analysts polled by FactSet expected a loss of $1.00.

Revenue for the quarter ended March 31 was $72,000, unchanged from a year earlier.

Analysts surveyed by FactSet expected $100,000.

The company said that as of March 31, it had $636.6 million in cash, cash equivalents, and short-term investments, which is expected to fund operations into H2 2027.

Price: 12.90, Change: -0.22, Percent Change: -1.68